Search

everythinglearnresearchcommunity

for

Search:↓

Ritlecitinib and baricitinib are effective for alopecia areata, but more research is needed to determine which is better.

Mycophenolate mofetil may improve lupus nephritis remission more than cyclophosphamide but with uncertain safety.

Upadacitinib significantly improved alopecia universalis and psoriatic arthritis in a patient.

Ablative fractional laser treatment nearly matches the gene reduction effects of topical vismodegib in skin cancer.

As of December 2021, the most effective COVID-19 treatments were monoclonal antibodies and possibly early-administered convalescent plasma, while several drugs were found ineffective or were still under evaluation.

Ruxolitinib helped a woman with a genetic mutation regrow her hair and improved her health.

Baricitinib is effective and safe for treating severe alopecia areata with ongoing use.

Tofacitinib is more effective than methotrexate for treating moderate-to-severe alopecia areata.

The IGRA test effectively detects past SARS-CoV-2 exposure, especially using nucleocapsid peptides.

Increasing the dose of baricitinib to 4 mg helps more patients with severe alopecia areata regrow hair.

Baricitinib was effective in treating a patient with dermatomyositis and hair loss.

Both individual and combined treatments of tofacitinib and corticosteroids can help regrow hair in moderate-to-severe alopecia areata, but ongoing treatment may be necessary.

PPARα agonists may help treat alopecia areata by reducing inflammation.

Immunotherapy for cancer caused a patient to develop a condition affecting hormone production, requiring ongoing hormone replacement therapy.

Baricitinib works better than methotrexate for severe alopecia areata.

Leflunomide and anthralin may effectively treat severe alopecia areata.

Finasteride reduces some inflammation in BPH but not all.

The combination of Typhonium flagelliforme extract and natural interferons effectively reduces tumor growth in mice.

The ALADIN score can predict how well patients with alopecia areata will respond to JAK inhibitor treatments.

Tofacitinib may be effective for treating hair loss caused by alopecia areata that doesn't respond to other treatments.

A JAK inhibitor improved both severe hair loss and chronic skin disease in one patient.

Tofacitinib is effective and has minor, reversible side effects for treating severe hair loss in Iran.

A woman with severe hair loss saw significant hair regrowth after adding platelet-rich plasma injections to her treatment with tofacitinib.

M50054 may help treat hepatitis and hair loss from chemotherapy.

A man developed temporary hair loss after taking a cancer drug, which might indicate a better treatment response.

Tofacitinib helped most teenagers in the study regrow hair with mild side effects.

The drug BAY 1158061 is safe, well-tolerated, and shows potential for treating diseases related to prolactin.

Most patients experienced mild to moderate skin problems during a trial for a desmoid tumor treatment.

Baricitinib is an effective treatment for severe alopecia areata.